Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catheter Precision (VTAK) EBIT (2017 - 2025)

Catheter Precision (VTAK) has disclosed EBIT for 9 consecutive years, with -$9.9 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 223.21% to -$9.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$21.1 million through Dec 2025, down 88.05% year-over-year, with the annual reading at -$21.1 million for FY2025, 88.05% down from the prior year.
  • EBIT for Q4 2025 was -$9.9 million at Catheter Precision, down from -$3.0 million in the prior quarter.
  • The five-year high for EBIT was -$2.6 million in Q4 2023, with the low at -$66.5 million in Q1 2023.
  • Average EBIT over 5 years is -$8.4 million, with a median of -$5.1 million recorded in 2022.
  • The sharpest move saw EBIT plummeted 1108.14% in 2023, then skyrocketed 96.07% in 2024.
  • Over 5 years, EBIT stood at -$8.3 million in 2021, then grew by 0.59% to -$8.2 million in 2022, then surged by 68.39% to -$2.6 million in 2023, then dropped by 17.48% to -$3.1 million in 2024, then plummeted by 223.21% to -$9.9 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$9.9 million, -$3.0 million, and -$4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.